H. Lundbeck A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLUN-B.CO research report →
About the company
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,315
- HQ
- Valby, DK
Price Chart
- Market Cap
- $33.99B
- P/E
- 11.51
- P/S
- 1.35
- P/B
- 1.66
- EV/EBITDA
- 5.51
- Div Yield
- 2.68%
- Gross Margin
- 78.95%
- Op Margin
- 27.86%
- Net Margin
- 14.71%
- ROE
- 14.81%
- ROIC
- 11.62%
- Revenue
- $24.35B · 10.67%
- Net Income
- $3.19B · 1.56%
- EPS
- $3.22 · 1.58%
- Op Income
- $6.34B
- FCF YoY
- 57.33%
- 52W High
- $47.78
- 52W Low
- $32.74
- 50D MA
- $42.55
- 200D MA
- $42.71
- Beta
- 0.22
- Avg Volume
- 756.94K
Get TickerSpark's AI analysis on HLUN-B.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HLUN-B.CO coverage
Recent articles, reports, and earnings notes.
No research on HLUN-B.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLUN-B.CO report →Similar companies
Peers in the same neighborhood.